NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for NeuroPace in a research note issued on Wednesday, May 28th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of $0.05 per share for the year, down from their prior estimate of $0.07. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace's FY2029 earnings at $0.37 EPS.
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The company had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%.
NPCE has been the topic of several other research reports. Wells Fargo & Company upped their price target on NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. upped their price target on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a research note on Wednesday, May 14th. Finally, HC Wainwright began coverage on NeuroPace in a research note on Wednesday. They set a "buy" rating and a $18.00 price target on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $15.50.
View Our Latest Report on NeuroPace
NeuroPace Price Performance
NeuroPace stock traded down $0.13 on Thursday, reaching $12.98. The company's stock had a trading volume of 285,244 shares, compared to its average volume of 159,779. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The company has a market cap of $425.73 million, a price-to-earnings ratio of -12.98 and a beta of 2.04. The business's fifty day moving average price is $12.83 and its 200 day moving average price is $12.16. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98.
Institutional Investors Weigh In On NeuroPace
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in NeuroPace in the fourth quarter valued at about $29,000. GAMMA Investing LLC bought a new stake in NeuroPace in the first quarter valued at about $53,000. Wells Fargo & Company MN increased its holdings in NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after purchasing an additional 2,279 shares during the last quarter. MetLife Investment Management LLC bought a new stake in NeuroPace in the fourth quarter valued at about $103,000. Finally, Cubist Systematic Strategies LLC bought a new stake in NeuroPace in the fourth quarter valued at about $112,000. Institutional investors own 78.83% of the company's stock.
Insider Activity at NeuroPace
In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the sale, the insider now owns 3,238,199 shares in the company, valued at approximately $51,325,454.15. This represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 22.20% of the stock is currently owned by corporate insiders.
NeuroPace Company Profile
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
See Also
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
